Addex Therapeutics Ltd. (ADXN) - Dilution Analysis

20-F filing | 147.8M shares outstanding

20-F filing | 128.3M shares outstanding

POS AM filing: This prospectus relates to the resale by the selling shareholder identified in this prospectus of up to an aggregate of 465,081 ADSs (representing 55,809,720 shares) consisting of Warrants with an exercise price of USD 20.00 per ADS and expiring, on April 5, 2028.

20-F filing | 125.2M shares outstanding

POS AM filing: This prospectus relates to the resale by the selling shareholder identified in this prospectus of up to an aggregate of 516,081 ADSs (representing 61,929,720 shares) consisting of (i) Warrants to purchase an aggregate of 55,809,720 shares, represented by 465,081 ADSs with an exercise price of USD 20.00 per ADS and expiring on April 5, 2028, and (ii) Pre-Funded Warrants to purchase up to 6,120,000 shares represented by 51,000 ADSs with an exercise price of USD 0.20 per ADS.

POS AM filing: This prospectus relates to the resale by the selling shareholder identified in this prospectus of up to an aggregate of 12,156,620 ADSs (representing 72,939,720 shares) consisting of (i) Ordinary Warrants to purchase up to an aggregate of 31,578,948 shares, represented by 5,263,158 ADSs with an exercise price of $1.00 per ADS; (ii) Pre-Funded Warrants to purchase up to 17,130,000 shares represented by 2,855,000 ADSs with an exercise price of $0.01 per ADS and (iii) Amended Warrants to purchase up to an aggregate of 24,230,772 shares, represented by 4,038,462 ADSs with an exercise price of $1.00 per ADS.

F-1 filing: This prospectus relates to the resale by the selling shareholder identified in this prospectus of up to an aggregate of 13,231,445 ADSs (representing 79,388,670 shares) consisting of (i) Ordinary Warrants to purchase up to an aggregate of 31,578,948 shares, represented by 5,263,158 ADSs, which are exercisable 90 days after the date of issuance at an exercise price of $1.00 per ADS; (ii) Pre-Funded Warrants to purchase up to 23,578,950 shares represented by 3,929,825 ADSs, which are exercisable 60 days after the date of issuance at an exercise price of $0.01 per ADS; and (iii) Amended Warrants to purchase up to an aggregate of 24,230,772 shares, represented by 4,038,462 ADSs, exercisable starting July 5, 2023 at an exercise price of $1.00 per ADS.

20-F filing | 77.1M shares outstanding

POS AM filing: This prospectus relates to the resale of American Depositary Shares (ADSs) representing shares deliverable upon the exercise of December 2021 Ordinary Warrants by the selling shareholder.

F-1 filing: This F-1 filing relates to the resale by the selling shareholder of up to an aggregate of 4,250,000 ADSs (representing 25,500,000 shares) consisting of (i) 2,500,000 ADSs (representing 15,000,000 ordinary shares) deliverable upon exercise of the Ordinary Warrants and (ii) 1,750,000 ADSs (representing 10,500,000 shares) deliverable upon the exercise of the Pre-Funded Warrants.

POS AM filing: This prospectus relates to the resale by the selling shareholder identified in this prospectus of up to an aggregate of 2,451,557 ADSs (representing 14,709,342 shares) consisting of (i) 1,538,462 ADSs (representing 9,230,772 shares) deliverable upon exercise of the Ordinary Warrants and (ii) 913,095 ADSs (representing 5,478,570 shares) deliverable upon the exercise of the Pre-Funded Warrants.

POS AM filing: This is a Post-Effective Amendment No. 2 to remove from registration all securities registered but not sold under the Registration Statement.

20-F filing | 37.9M shares outstanding

F-1 filing: This prospectus relates to the resale by the selling shareholder of up to an aggregate of 2,451,557 ADSs (representing 14,709,342 shares) consisting of shares deliverable upon exercise of the Ordinary Warrants and the Pre-Funded Warrants.

F-3 filing: Addex Therapeutics Ltd is offering $150,000,000 of shares and 7,704,600 shares are being offered by the selling shareholder.

20-F filing | 27.1M shares outstanding

F-1 filing: This F-1 filing describes a global offering of shares in the form of ADSs and shares in a European private placement, with an underwriter option to purchase additional shares. The net proceeds will be used to advance the company's preclinical and clinical pipeline.

POS AM filing: This is a POS AM filing detailing the expenses expected to be incurred in connection with the registration of shares.

20-F filing | 32.8M shares outstanding